Anavex Life Sciences Corp (AVXL)

[MayoMobile]

Cohen’s D Effect Size & Anavex

Would strongly recommend reading this: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791668/

Especially the portion of Cohen D.

Basically, Cohen D effect size is a much better indicator of a successful trial over P values.

P values with corroborating good effect size via Cohen D is best case. We have done this a lot… most of our Cohen D effect sizes in AD and Rett have very nearly approached 1.0 or exceeded 1.0. These are large-very large effect sizes. Keep a look out for a peer review including PDD effect size and actigraphy.

Anavex Cohen’s D

Alzheimer’s 2a (week 57):
MMSE in all compared to SOC: 0.57
MMSE in all: 0.65
MMSE in S1R WT, and >20 baseline: 1.01
MMSE in top patients, ^ and COMT: 1.05
ADCS in all compared to SOC: 0.18
ADCS in all: 0.22
ADCS in S1R WT, and >20 baseline: 0.76
ADCS in top patients, ^ and COMT: 0.93

Rett RS-001 total dosed
RSBQ: 1.11
ADAMS: 1.31

Rett RS-001 PK cohort
RSBQ: 1.47
Glutamate: 1.11